This website is an international information resource intended for international healthcare professionals outside the United States of America (US) and the United Kingdom (UK) who are interested in information about Boehringer Ingelheim oncology.
While the Internet serves a global community, the pharmaceutical industry is subject to country-specific regulatory considerations. This means that compound status or the registration status and approved product labels of the products described within this website may not be the same in different countries.
Information about approved products on this website is derived from the Summary of Product Characteristics (SPC) for each product in the EU. It is not country-specific and may vary from the approved label in the country where you are located. Please refer to your local Prescribing Information for full details.
By clicking on the link below you are declaring and confirming that you are a healthcare professional outside the United States of America and the United Kingdom and have read and understood this disclaimer.
The 2018 European Lung Cancer Congress (ELCC) is taking place on 11-14 April 2018 at Palexpo Exhibition Centre, Geneva, Switzerland.
Boehringer Ingelheim will be presenting a symposium entitled ‘Points of view: opportunities and remaining hurdles in thoracic malignancies’ on the 13th of April, 13:00-14:00 in Room C. Come along to hear about clinical perspectives on the challenges faced in treating NSCLC and MPM from esteemed experts: Dean A. Fennell, Martin Schuler and Nicolas Girard.
You can also visit us at booth 10a in the exhibition area to learn more about Boehringer Ingelheim’s collaborative approach to research and how we are already making the future brighter for people with cancer.
The full ELCC 2018 programme can be found here.
Please return to the page nearer the event for further details on Boehringer Ingelheim’s events at ELCC.
Download the symposium agenda below
ELCC 2018 Points of view: opportunities and remaining hurdles in thoracic malignancies
Afatinib in patients with EGFR mutation-positive (EGFRm+) NSCLC harbouring uncommon mutations: overview of clinical data (Presentation #158P)
Märten et al.
Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7 (Presentation #143PD)
Yang et al.
Second-line afatinib for patients with locally advanced or metastatic NSCLC harbouring common EGFR mutations: a Phase IV study (Presentation #157P)
Thongprasert et al.
Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma (MPM): Phase II biomarker data from the LUME Meso study (Presentation #213O)
Pavlakis et al.
*Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.
¶Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.
© 2018 Boehringer Ingelheim International GmbH. All rights reserved.
Last updated: February 2018
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue